Liminatus Pharma (LIMN) has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework. This internal review is part of Liminatus’s continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments-including blockchain-based assets-that may enhance treasury efficiency and diversify non-operating capital reserves.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIMN: